To determine whether PTEN genomic losses were also more prevalent in metastatic disease, as predicted by the above reports, we selected a small cohort of paired primary prostate adenocarcinomas and metastatic adenocarcinoma in the regional lymph nodes derived from the same patient. Here, PTEN is linked to metastatic neoplasm.